HLS Therapeutics Inc.
HLS Therapeutics Inc. (HLS.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hls.to · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for HLS Therapeutics Inc. (HLS.TO) measures how much investors pay for each dollar of the company's trailing earnings. HLS.TO's current PE ratio of N/A is calculated by dividing its stock price of $4.41 by its TTM earnings per share of -$0.33.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 7 fiscal years · Front-end computedMinQ1 · 25%22.0x
MedianQ3 · 75%165.9x
Max
At N/A, HLS.TO's current P/E is lower than in 0% of its annual fiscal year readings over the past 7 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
HLS Therapeutics Inc.You HLS.TO | $138M | N/A | — | -$0.33 |
 BioNxt Solutions Inc. BNXT.CN | $53M | N/A | — | -$0.06 |
 Cardiol Therapeutics Inc. CRDL.TO | $169M | N/A | — | -$0.39 |
 Grown Rogue International Inc. GRIN.CN | $165M | 16.92x | +13.6% | $0.03 |
 Helix BioPharma Corp. HBP.TO | $117M | N/A | — | -$0.09 |
 Jushi Holdings Inc. JUSH.CN | $148M | N/A | — | -$0.35 |
 Cannara Biotech Inc. LOVE.V | $181M | 12.86x | -13.6% | $0.14 |
Industry Average 2 peers with valid PE | — | 14.89x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.40 | — | |
2024-12-31 FY2024 | — | $-0.62 | — | |
2023-12-31 FY2023 | — | $-0.85 | — | |
2022-12-31 FY2022 | — | $-0.73 | — | |
2021-12-31 FY2021 | — | $-0.41 | — | |
2020-12-31 FY2020 | — | $-0.48 | — | |
2019-12-31 FY2019 | — | $-0.67 | — | |
2018-12-31 FY2018 | — | $-0.92 | — | |
2017-12-31 FY2017 | — | $-0.24 | — | |
2016-12-31 FY2016 | — | $-0.04 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for HLS Therapeutics Inc. (HLS.TO) measures how much investors pay for each dollar of the company's trailing earnings. HLS.TO's current PE ratio of N/A is calculated by dividing its stock price of $4.41 by its TTM earnings per share of -$0.33.
Frequently asked questions
HLS.TO pe ratio · 6 questionsHLS.TO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $4.41 and TTM EPS of -$0.33. Data sourced from Financial Modeling Prep via HLS.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · HLS Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08